|Follow us :|
Luai Al Bakour
El Temamy Pharmacy
Akoni Hijyen Teknolojileri Sanayi ve Dış Ticaret LTD. ŞTİ
Britton Chance Center for Biomedical Photonics
Arabian Trade Center - ATC
Medical Facility (32206):
Legality International. (Pvt.) Ltd.
MainYou must sign in to use this servcie
Feedback - Please use the form below to send your query or comment
You must sign in to use this servcie
Susceptible infections,Severe campylobacter enteritis,Pertussis,Diphtheria,Chanroid,Legionnaire’s disease,Chlamydial infections,Legionnaire’s disease,Bronchitis,Pneumonia,Sinusitis,Trench fever,Acne,Prophylaxis of streptococcal infections in patients with evidence of rheumatic fever or heart disease,Treatment and prophylaxis of neonatal conjunctivitis.
Hypersensitivity; porphyria; hepatic impairment; pregnancy.
Rash, urticaria; nausea, vomiting, GI discomfort; ototoxicity; central neurotoxicity; agranulocytosis; arrhythmias; pancreatitis. Potentially Fatal: Hepatotoxicity, cholestatic jaundice; raised serum transaminases; eosinophilia.
May antagonise therapeutic effects lincomycin and clindamycin. Concurrent usage may lead to increased absorption of alcohol. Potentially Fatal: May potentiate actions of neuromuscular blockers, oral anticoagulants, ciclosporin, theophylline. Terfenadine, astemizole, cisapride toxicity increased. Food Interaction Increased absorption when taken with meals. Lab Interference False-positive urinary catecholamines. Falsely elevated serum-aspartate aminotransferase values.
Increased risk of cholestatic hepatitis when treatment is >10 days or in patients with previous history of erythromycin usage. History of hepatic disorders; arrhythmias; prolonged QT interval; lactation. Monitor liver function. Avoid estolate in liver impairment. Caution when using lactobionate in patients with severe renal impairment. May aggravate muscle weakness in patients with myasthenia gravis. pregnancy: Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters).
SOLUTION FOR INJECTION
Dosage and AdministrationYou must sign in to use this servcie
Technical DescriptionYou must sign in to use this servcie
Yaser Habrawi , F.R.C.S.Ed
Dr. Samer Al-Jneidy
Dr. Faisal Dibsi
Samir Moussa M.D.
Dr. Hani Najjar
Dr. Tahsin Martini
Dr. Talal Sabouni
Dr . Dirar Abboud